Literature DB >> 20147897

Applying physiological and biochemical concepts to optimize biological drug development.

P J Lowe1.   

Abstract

Posology--the science of dose and regimen--is a critical part of drug development. It is concerned with ensuring that patients experience significant clinical benefit without intolerable adverse effects. It has become apparent, in the case of certain biologics, that one can directly quantitate occupancy or target capture and relate these to clinical responses. With mathematical models that integrate binding concepts with clinical effects, potential posologies can be quickly explored through simulation, thereby liberating research teams from the traditional constraints and simultaneously stimulating innovation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20147897     DOI: 10.1038/clpt.2009.302

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  5 in total

1.  Factors influencing magnitude and duration of target inhibition following antibody therapy: implications in drug discovery and development.

Authors:  Anjaneya P Chimalakonda; Rajbharan Yadav; Punit Marathe
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

2.  Exposure-response relationship of AMG 386 in combination with weekly paclitaxel in recurrent ovarian cancer and its implication for dose selection.

Authors:  Jian-Feng Lu; Erik Rasmussen; Beth Y Karlan; Ignace B Vergote; Lynn Navale; Mita Kuchimanchi; Rebeca Melara; Daniel E Stepan; David M Weinreich; Yu-Nien Sun
Journal:  Cancer Chemother Pharmacol       Date:  2012-01-01       Impact factor: 3.333

3.  Quantitative prediction of human pharmacokinetics for monoclonal antibodies: retrospective analysis of monkey as a single species for first-in-human prediction.

Authors:  Jennifer Q Dong; David H Salinger; Christopher J Endres; John P Gibbs; Cheng-Pang Hsu; Brian J Stouch; Eunju Hurh; Megan A Gibbs
Journal:  Clin Pharmacokinet       Date:  2011-02       Impact factor: 6.447

4.  Dose-biomarker-response modeling of the anticancer effect of ethaselen in a human non-small cell lung cancer xenograft mouse model.

Authors:  Suo-Fu Ye; Jian Li; Shuang-Min Ji; Hui-Hui Zeng; Wei Lu
Journal:  Acta Pharmacol Sin       Date:  2016-12-05       Impact factor: 6.150

5.  A Tutorial on Target-Mediated Drug Disposition (TMDD) Models.

Authors:  P Dua; E Hawkins; P H van der Graaf
Journal:  CPT Pharmacometrics Syst Pharmacol       Date:  2015-06-15
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.